News

You are here

Feb 05, 2016

From the 4th to 6th of April, Iproteos CEO, Teresa Tarragó, will be in Stockholm (Sweden) participating on the next BIO-Europe Spring. Teresa will be delighted to meet with companies and other agents of the sector interested on the IPRO Technology. If you want to discover what Iproteos can do to boost your R&D, contact us!

Feb 05, 2016

During the first week of March, Sandra Bertran, our PhD student, will participate in the 1st ECMED Advanced Training Course. ECMED is a European Consortium where Iproteos participates. It is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 642881.

Dec 31, 2015

On December Iproteos took another step in its development. We move to a larger, new and brilliant lab, located at Cluster II of the Barcelona Science Park (Parc Científic de Barcelona). The move was done in two days, and full boxes were going up&down.

Oct 22, 2015

Teresa Tarragó is attending next BIO-Europe, which will be held November 2-4 on Munich. The conference is the largest partnering event in Europe. At the previous edition, 3,234 delegates from 54 countries attended the congress. Iproteos CEO will participate at the partnering event, an extraordinary opportunity to interact with other agents of the sector. This is the opportunity to know more about the IPRO Technology and to discover how it can be applied into your R&D.

Oct 22, 2015

Next 2-6 November the first ECMED Workshop will take place. ECMED is the acronym for “The Extracellular Matrix in Epileptogenesis” a consortium formed by 11 organizations from all over Europe with a joint objective: to design, validate and bring into practice new innovative therapeutic strategies against epilepsy. The first workshop, entitled “Understanding epilepsy and Practical workshop 1” will be held in Magdeburg, Germany. Delegates from the consortium members will gather together in order to delve into epilepsy.

Oct 22, 2015

Roger Prades, Iproteos CSO will participate at the Barcelona BioMed Conference “Blood Brain Barrier” that will be held next November 2-4. Roger will give a short talk that will be entitled “IPR19: a prolyl oligopeptidase inhibitor for the treatment of cognitive impairment associated with schizophrenia”. The talk will be delivered on Thursday 3 in the afternoon, at the “Institut d’Estudis Catalans”. This Barcelona BioMed Conference is organized by Prof. Ernest Giralt (IRB Barcelona, Spain) and Prof.